{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:43:14Z","timestamp":1790664194197,"version":"4.1.0"},"reference-count":166,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T00:00:00Z","timestamp":1620777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003765","name":"Universit\u00e0 Campus Bio-Medico di Roma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003765","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>In type 2 diabetes, anti-thrombotic management is challenging, and current anti-platelet agents have demonstrated reduced efficacy. Old and new anti-diabetic drugs exhibited\u2014besides lowering blood glucose levels\u2014direct and indirect effects on platelet function and on thrombotic milieu, eventually conditioning cardiovascular outcomes. The present review summarizes existing evidence on the effects of glucose-lowering agents on platelet properties, addressing pre-clinical and clinical research, as well as drug\u2013drug interactions with anti-platelet agents. We aimed at expanding clinicians\u2019 understanding by highlighting new opportunities for an optimal management of patients with diabetes and cardiovascular disease. We suggest how an improvement of the thrombotic risk in this large population of patients may be achieved by a careful and tailored combination of anti-diabetic and anti-platelet therapies.<\/jats:p>","DOI":"10.3389\/fphar.2021.670155","type":"journal-article","created":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T03:00:22Z","timestamp":1620788422000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":48,"title":["Platelet Effects of Anti-diabetic Therapies: New Perspectives in the Management of Patients with Diabetes and Cardiovascular Disease"],"prefix":"10.3389","volume":"12","author":[{"given":"Annunziata","family":"Nusca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Tuccinardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Pieralice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Giannone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Carpenito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavinia","family":"Monte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikiko","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Cavallari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Maddaloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Paolo","family":"Ussia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Manfrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Grigioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.peptides.2018.09.002","article-title":"Glucagon-like Peptide-1 Receptor Action in the Vasculature","volume":"111","author":"Almutairi","year":"2019","journal-title":"Peptides"},{"key":"B2","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jacc.2006.03.038","article-title":"Insulin Therapy Is Associated with Platelet Dysfunction in Patients with Type 2 Diabetes Mellitus on Dual Oral Antiplatelet Treatment","volume":"48","author":"Angiolillo","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/j.jacc.2006.11.044","article-title":"Variability in Individual Responsiveness to Clopidogrel","volume":"49","author":"Angiolillo","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.jacc.2014.06.1170","article-title":"Impaired Responsiveness to the Platelet P2Y12 Receptor Antagonist Clopidogrel in Patients with Type 2 Diabetes and Coronary Artery Disease","volume":"64","author":"Angiolillo","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.jcin.2011.03.001","article-title":"Optimizing Platelet Inhibition in Clopidogrel Poor Metabolizers","volume":"4","author":"Angiolillo","year":"2011","journal-title":"JACC: Cardiovasc. Intervent."},{"key":"B6","doi-asserted-by":"publisher","first-page":"S98","DOI":"10.2337\/dc20-S009","article-title":"American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020","volume":"43","author":"Anon","year":"20202020","journal-title":"Diabetes Care"},{"key":"B7","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12933-018-0750-8","article-title":"Glycemic Control by the SGLT2 Inhibitor Empagliflozin Decreases Aortic Stiffness, Renal Resistivity Index and Kidney Injury","volume":"17","author":"Aroor","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"706","DOI":"10.2337\/dc16-1943","article-title":"Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational Studies","volume":"40","author":"Azoulay","year":"2017","journal-title":"Dia Care"},{"key":"B9","doi-asserted-by":"publisher","first-page":"755","DOI":"10.2337\/diacare.15.6.755","article-title":"Biguanides and NIDDM","volume":"15","author":"Bailey","year":"1992","journal-title":"Diabetes Care"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1160\/TH16-07-0586","article-title":"Glucagon-like Peptide 1-related Peptides Increase Nitric Oxide Effects to Reduce Platelet Activation","volume":"117","author":"Barale","year":"2017","journal-title":"Thromb. Haemost."},{"key":"B11","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.thromres.2019.06.010","article-title":"Hypercholesterolemia Impairs the Glucagon-like Peptide 1 Action on Platelets: Effects of a Lipid-Lowering Treatment with Simvastatin","volume":"180","author":"Barale","year":"2019","journal-title":"Thromb. Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1016\/j.jacc.2006.08.040","article-title":"Insulin Resistance as a Determinant of Platelet Activation in Obese Women","volume":"48","author":"Basili","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/cvr\/cvx149","article-title":"Cardiac Effects of SGLT2 Inhibitors: the Sodium Hypothesis","volume":"114","author":"Bertero","year":"2018","journal-title":"Cardiovasc. Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e000227","DOI":"10.1136\/bmjdrc-2016-000227","article-title":"Dipeptidyl Peptidase-4 Inhibition by Saxagliptin Prevents Inflammation and Renal Injury by Targeting the Nlrp3\/ASC Inflammasome","volume":"4","author":"Birnbaum","year":"2016","journal-title":"BMJ Open Diab Res. Care"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1111\/j.1538-7836.2005.01551.x","article-title":"Pioglitazone Protects against Thrombosis in a Mouse Model of Obesity and Insulin Resistance","volume":"3","author":"Bodary","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"B16","doi-asserted-by":"publisher","first-page":"880","DOI":"10.2337\/diabetes.54.3.880","article-title":"Thiazolidinediones Upregulate Fatty Acid Uptake and Oxidation in Adipose Tissue of Diabetic Patients","volume":"54","author":"Boden","year":"2005","journal-title":"Diabetes"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1016\/j.jacc.2011.06.059","article-title":"Impact of Platelet Reactivity on Clinical Outcomes after Percutaneous Coronary Intervention","volume":"58","author":"Brar","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.2337\/db15-1141","article-title":"Glucagon-Like Peptide 1 Receptor Activation Attenuates Platelet Aggregation and Thrombosis","volume":"65","author":"Cameron-Vendrig","year":"2016","journal-title":"Diabetes"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.2337\/db11-1243","article-title":"Platelet Isoprostane Overproduction in Diabetic Patients Treated with Aspirin","volume":"61","author":"Cangemi","year":"2012","journal-title":"Diabetes"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/3968206","article-title":"Modulation of Circulating MicroRNAs Levels during the Switch from Clopidogrel to Ticagrelor","volume":"2016","author":"Carino","year":"2016","journal-title":"Biomed. Res. Int."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e000920","DOI":"10.1161\/JAHA.114.000920","article-title":"Different Degrees of NADPH Oxidase 2 Regulation and In Vivo Platelet Activation: Lesson from Chronic Granulomatous Disease","volume":"3","author":"Carnevale","year":"2014","journal-title":"Jaha"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e3124","DOI":"10.1002\/dmrr.3124","article-title":"Cardiovascular Effects of SGLT\u20102 Inhibitors: What We Have Learned from Cardiovascular Outcome Trials and what We Still Need to Understand","volume":"35","author":"Cavallari","year":"2019","journal-title":"Diabetes Metab. Res. Rev."},{"key":"B171","doi-asserted-by":"publisher","first-page":"dgaa427","DOI":"10.1210\/clinem\/dgaa427","article-title":"The vicious circle of left ventricular dysfunction and diabetes: From pathophysiology to emerging treatments","volume":"105","author":"Cavallari","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B23","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1161\/CIRCULATIONAHA.114.014796","article-title":"Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death","volume":"132","author":"Cavender","year":"2015","journal-title":"Circulation"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.2337\/dc12-2469","article-title":"Glucagon-like Peptide 1 Reduces Endothelial Dysfunction, Inflammation, and Oxidative Stress Induced by Both Hyperglycemia and Hypoglycemia in Type 1 Diabetes","volume":"36","author":"Ceriello","year":"2013","journal-title":"Diabetes Care"},{"key":"B25","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1001\/jama.290.4.486","article-title":"Acarbose Treatment and the Risk of Cardiovascular Disease and Hypertension in Patients with Impaired Glucose Tolerance","volume":"290","author":"Chiasson","year":"2003","journal-title":"JAMA"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/dom.12572","article-title":"Effects of Empagliflozin on Blood Pressure and Markers of Arterial Stiffness and Vascular Resistance in Patients with Type 2 Diabetes","volume":"17","author":"Chilton","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"B27","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1159\/000318024","article-title":"Effect of Pioglitazone on Platelet Aggregation in a Healthy Cohort","volume":"116","author":"Chokesuwattanaskul","year":"2010","journal-title":"Cardiology"},{"key":"B28","first-page":"420","article-title":"Effect of Glycaemic Control, Metformin and Gliclazide on Platelet Density and Aggregability in Recently Diagnosed Type 2 (Non-insulin-dependent) Diabetic Patients","volume":"15","author":"Collier","year":"1989","journal-title":"Diabete Metab."},{"key":"B29","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on Diabetes, Pre-diabetes, and Cardiovascular Diseases Developed in Collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur. Heart J."},{"key":"B30","doi-asserted-by":"publisher","first-page":"A322","DOI":"10.1007\/s001250051445","article-title":"NVP-LAF237, a Dipeptidyl Peptidase IV Inhibitor, Improves Glucose Tolerance and Delays Gastric Emptying in Obese Insulin Resistant Cynomolgus Monkeys","volume":"52","author":"Dardik","year":"2003","journal-title":"Diabetes"},{"key":"B31","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1161\/01.cir.99.2.224","article-title":"In vivo formation of 8-Iso-Prostaglandin F2alpha and Platelet Activation in Diabetes Mellitus: Effects of Improved Metabolic Control and Vitamin E Supplementation","volume":"99","author":"Dav\u00ec","year":"1999","journal-title":"Circulation"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1056\/NEJM199006213222503","article-title":"Thromboxane Biosynthesis and Platelet Function in Type II Diabetes Mellitus","volume":"322","author":"Dav\u00ec","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"B33","first-page":"335","article-title":"Changes in Platelet Aggregation Caused by Glyburide in Diabetic Patients","volume":"6","author":"De Bellis","year":"1984","journal-title":"Clin. Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1056\/NEJMoa1010949","article-title":"Pioglitazone for Diabetes Prevention in Impaired GlucoseTolerance","volume":"364","author":"DeFronzo","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.diabres.2004.10.007","article-title":"A Comparison of the Effects of Pioglitazone and Rosiglitazone Combined with Glimepiride on Prothrombotic State in Type 2 Diabetic Patients with the Metabolic Syndrome","volume":"69","author":"Derosa","year":"2005","journal-title":"Diabetes Res. Clin. Pract."},{"key":"B36","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/21224","article-title":"Activation of Nitric Oxide Synthase in Endothelial Cells by Akt-dependent Phosphorylation","volume":"399","author":"Dimmeler","year":"1999","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3109\/09537104.2012.674165","article-title":"The Effect of Metformin on Mean Platelet Volume in D\u0131abet\u0131c Patients","volume":"24","author":"Dolas\u0131k","year":"2013","journal-title":"Platelets"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary Prevention of Macrovascular Events in Patients with Type 2 Diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a Randomised Controlled Trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"The Lancet"},{"key":"B39","first-page":"1","volume-title":"FDA Drug Safety Communication\u202f: FDA Adds Warnings about Heart Failure Risk to Labels of Type 2 Diabetes Medicines Containing Saxagliptin and Alogliptin","year":"2016"},{"key":"B40","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1161\/01.ATV.0000199519.37089.a0","article-title":"Platelet Inhibition by Insulin Is Absent in Type 2 Diabetes Mellitus","volume":"26","author":"Ferreira","year":"2006","journal-title":"Atvb"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","article-title":"Heart Failure Outcomes with Empagliflozin in Patients with Type 2 Diabetes at High Cardiovascular Risk: Results of the EMPA-REG OUTCOMEtrial","volume":"37","author":"Fitchett","year":"2016","journal-title":"Eur. Heart J."},{"key":"B42","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/dmrr.794","article-title":"Decreasedin Vivo Oxidative Stress and Decreased Platelet Activation Following Metformin Treatment in Newly Diagnosed Type 2 Diabetic Subjects","volume":"24","author":"Formoso","year":"2008","journal-title":"Diabetes Metab. Res. Rev."},{"key":"B43","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 Diabetes","volume":"348","author":"Gaede","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1002\/dmrr.282","article-title":"Metformin Decreases Platelet Superoxide Anion Production in Diabetic Patients","volume":"18","author":"Gargiulo","year":"2002","journal-title":"Diabetes Metab. Res. Rev."},{"key":"B45","doi-asserted-by":"publisher","first-page":"372","DOI":"10.2337\/dc06-1625","article-title":"Platelet Response to Clopidogrel Is Attenuated in Diabetic Patients Undergoing Coronary Stent Implantation","volume":"30","author":"Geisler","year":"2007","journal-title":"Diabetes Care"},{"key":"B46","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa1203858","article-title":"Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia","volume":"367","author":"Gerstein","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of Intensive Glucose Lowering in Type 2 Diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/0168-8227(89)90058-2","article-title":"Study of the Effect of Metformin on Platelet Aggregation in Insulin-dependent Diabetics","volume":"6","author":"Gin","year":"1989","journal-title":"Diabetes Res. Clin. Pract."},{"key":"B49","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1161\/01.cir.57.3.549","article-title":"The Rate-Pressure Product as an Index of Myocardial Oxygen Consumption during Exercise in Patients with Angina Pectoris","volume":"57","author":"Gobel","year":"1978","journal-title":"Circulation"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.2337\/dc09-0354","article-title":"Effects of Acute Hypoglycemia on Inflammatory and Pro-atherothrombotic Biomarkers in Individuals with Type 1 Diabetes and Healthy Individuals","volume":"33","author":"Gogitidze Joy","year":"2010","journal-title":"Diabetes Care"},{"key":"B51","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.cca.2013.11.028","article-title":"Acetylsalicylic Acid Therapy: Influence of Metformin Use and Other Variables on Urinary 11-dehydrothromboxane B2 Levels","volume":"429","author":"Gon\u00e7alves","year":"2014","journal-title":"Clinica Chim. Acta"},{"key":"B52","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/s0735-1097(02)02972-8","article-title":"Acute, Short-Term Hyperglycemia Enhances Shear Stress-Induced Platelet Activation in Patients with Type II Diabetes Mellitus","volume":"41","author":"Gresele","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.2337\/dc09-2013","article-title":"Hyperglycemia-induced Platelet Activation in Type 2 Diabetes Is Resistant to Aspirin but Not to a Nitric Oxide-Donating Agent","volume":"33","author":"Gresele","year":"2010","journal-title":"Diabetes Care"},{"key":"B55","doi-asserted-by":"publisher","first-page":"565","DOI":"10.3109\/09537104.2012.721907","article-title":"Sitagliptin: Anti-platelet Effect in Diabetes and Healthy Volunteers","volume":"23","author":"Gupta","year":"2012","journal-title":"Platelets"},{"key":"B56","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/s0195-668x(03)00468-8","article-title":"Acarbose Reduces the Risk for Myocardial Infarction in Type 2 Diabetic Patients: Meta-Analysis of Seven Long-Term Studies","volume":"25","author":"Hanefeld","year":"2004","journal-title":"Eur. Heart J."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1161\/01.STR.0000125864.01546.f2","article-title":"Acarbose Slows Progression of Intima-Media Thickness of the Carotid Arteries in Subjects with Impaired Glucose Tolerance","volume":"35","author":"Hanefeld","year":"","journal-title":"Stroke"},{"key":"B58","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s10557-008-6091-1","article-title":"Effect of Acarbose on Vascular Disease in Patients with Abnormal Glucose Tolerance","volume":"22","author":"Hanefeld","year":"2008","journal-title":"Cardiovasc. Drugs Ther."},{"key":"B59","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3109\/09537104.2010.530359","article-title":"Sulfonylureas and On-Clopidogrel Platelet Reactivity in Type 2 Diabetes Mellitus Patients","volume":"22","author":"Harmsze","year":"2011","journal-title":"Platelets"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1161\/01.ATV.0000176192.16951.9a","article-title":"Rapid Effects of Rosiglitazone Treatment on Endothelial Function and Inflammatory Biomarkers","volume":"25","author":"Hetzel","year":"2005","journal-title":"Atvb"},{"key":"B61","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S2213-8587(17)30309-1","article-title":"Effects of Acarbose on Cardiovascular and Diabetes Outcomes in Patients with Coronary Heart Disease and Impaired Glucose Tolerance (ACE): a Randomised, Double-Blind, Placebo-Controlled Trial","volume":"5","author":"Holman","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes","volume":"377","author":"Holman","year":"","journal-title":"N. Engl. J. Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/S0140-6736(09)60953-3","article-title":"Rosiglitazone Evaluated for Cardiovascular Outcomes in Oral Agent Combination Therapy for Type 2 Diabetes (RECORD): a Multicentre, Randomised, Open-Label Trial","volume":"373","author":"Home","year":"2009","journal-title":"The Lancet"},{"key":"B64","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1056\/NEJMoa073394","article-title":"Rosiglitazone Evaluated for Cardiovascular Outcomes - an Interim Analysis","volume":"357","author":"Home","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.2337\/diabetes.47.9.1494","article-title":"Differential Effect of the Antidiabetic Thiazolidinediones Troglitazone and Pioglitazone on Human Platelet Aggregation Mechanism","volume":"47","author":"Ishizuka","year":"1998","journal-title":"Diabetes"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1124\/dmd.116.070375","article-title":"Clopidogrel Markedly Increases Plasma Concentrations of CYP2C8 Substrate Pioglitazone","volume":"44","author":"Itkonen","year":"2016","journal-title":"Drug Metab. Disposition"},{"key":"B67","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1093\/eurheartj\/ehq325","article-title":"Ticagrelor vs. Clopidogrel in Patients with Acute Coronary Syndromes and Diabetes: a Substudy from the PLATelet Inhibition and Patient Outcomes (PLATO) Trial","volume":"31","author":"James","year":"2010","journal-title":"Eur. Heart J."},{"key":"B68","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/0026-0495(92)90093-p","article-title":"Effects of Gliclazide on Platelet Reactivity and Free Radicals in Type II Diabetic Patients: Clinical Assessment","volume":"41","author":"Jennings","year":"1992","journal-title":"Metabolism"},{"key":"B69","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.2337\/db14-1729","article-title":"Effects of Acute and Antecedent Hypoglycemia on Endothelial Function and Markers of Atherothrombotic Balance in Healthy Humans","volume":"64","author":"Joy","year":"2015","journal-title":"Diabetes"},{"key":"B70","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12902-015-0005-6","article-title":"The Effects of Treatment with Liraglutide on Atherothrombotic Risk in Obese Young Women with Polycystic Ovary Syndrome and Controls","volume":"15","author":"Kahal","year":"2015","journal-title":"BMC Endocr. Disord."},{"key":"B71","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1080\/09537100120078368","article-title":"The Possible Association of In Vivo Leukocyte-Platelet Heterophilic Aggregate Formation and the Development of Diabetic Angiopathy","volume":"12","author":"Kaplar","year":"2001","journal-title":"Platelets"},{"key":"B72","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1161\/CIRCULATIONAHA.119.040130","article-title":"Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus","volume":"139","author":"Kato","year":"2019","journal-title":"Circulation"},{"key":"B73","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1046\/j.1365-2125.1999.00092.x","article-title":"The UK Prospective Diabetes Study (UKPDS): Clinical and Therapeutic Implications for Type 2 Diabetes","volume":"48","author":"King","year":"1999","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/0002-9343(81)90585-4","article-title":"Sulfonylureas and Platelet Function","volume":"70","author":"Klaff","year":"1981","journal-title":"Am. J. Med."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.metabol.2009.12.004","article-title":"Effects of Gliclazide on Platelet Aggregation and the Plasminogen Activator Inhibitor Type 1 Level in Patients with Type 2 Diabetes Mellitus","volume":"59","author":"Konya","year":"2010","journal-title":"Metabolism"},{"key":"B76","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1001\/archinternmed.2009.20","article-title":"Long-term Effects of Metformin on Metabolism and Microvascular and Macrovascular Disease in Patients with Type 2 Diabetes Mellitus","volume":"169","author":"Kooy","year":"2009","journal-title":"Arch. Intern. Med."},{"key":"B77","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2165\/00002018-199411040-00002","article-title":"Comparative Tolerability Profiles of Oral Antidiabetic Agents","volume":"11","author":"Krentz","year":"1994","journal-title":"Drug Saf."},{"key":"B78","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00395-011-0233-5","article-title":"Loss of DPP4 Activity Is Related to a Prothrombogenic Status of Endothelial Cells: Implications for the Coronary Microvasculature of Myocardial Infarction Patients","volume":"107","author":"Krijnen","year":"2012","journal-title":"Basic Res. Cardiol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, Mortality, and Kidney Outcomes with GLP-1 Receptor Agonists in Patients with Type 2 Diabetes: a Systematic Review and Meta-Analysis of Cardiovascular Outcome Trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/j.1463-1326.2010.01349.x","article-title":"Effect of Metformin on Cardiovascular Events and Mortality: a Meta-Analysis of Randomized Clinical Trials","volume":"13","author":"Lamanna","year":"2011","journal-title":"Diabetes Obes. Metab."},{"key":"B81","doi-asserted-by":"publisher","first-page":"114276","DOI":"10.1016\/j.bcp.2020.114276","article-title":"The Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors Synergize with Nitric Oxide and Prostacyclin to Reduce Human Platelet Activation","volume":"182","author":"Lescano","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.cardiores.2004.11.027","article-title":"The Effects of PPAR-? Ligand Pioglitazone on Platelet Aggregation and Arterial Thrombus Formation","volume":"65","author":"Li","year":"2005","journal-title":"Cardiovasc. Res."},{"key":"B83","doi-asserted-by":"publisher","first-page":"585612","DOI":"10.3389\/fphar.2020.585612","article-title":"Linagliptin Regulates the Mitochondrial Respiratory Reserve to Alter Platelet Activation and Arterial Thrombosis","volume":"11","author":"Li","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ijcard.2012.04.087","article-title":"Vildagliptin Inhibits Oxidative Stress and Vascular Damage in Streptozotocin-Induced Diabetic Rats","volume":"158","author":"Maeda","year":"2012","journal-title":"Int. J. Cardiol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1136\/bmj.314.7093.1512","article-title":"Prospective Randomised Study of Intensive Insulin Treatment on Long Term Survival after Acute Myocardial Infarction in Patients with Diabetes Mellitus","volume":"314","author":"Malmberg","year":"1997","journal-title":"BMJ"},{"key":"B86","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B87","doi-asserted-by":"publisher","first-page":"740","DOI":"10.7326\/M15-2650","article-title":"Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes","volume":"164","author":"Maruthur","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"B88","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1177\/1479164115570301","article-title":"Design and Baseline Characteristics of the CARdiovascular Outcome Trial of LINAgliptin versus Glimepiride in Type 2 Diabetes (CAROLINA)","volume":"12","author":"Marx","year":"2015","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"B89","doi-asserted-by":"publisher","first-page":"774","DOI":"10.5551\/jat.7666","article-title":"Effect of Enhanced Glycemic Control with Saxagliptin on Endothelial Nitric Oxide Release and CD40 Levels in Obese Rats","volume":"18","author":"Mason","year":"2011","journal-title":"Jat"},{"key":"B90","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1159\/000051074","article-title":"Insulin Action in the Vasculature: Physiology and Pathophysiology","volume":"38","author":"Mather","year":"2001","journal-title":"J. Vasc. Res."},{"key":"B91","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jacc.2011.07.053","article-title":"A Dipeptidyl Peptidase-4 Inhibitor, Des-Fluoro-Sitagliptin, Improves Endothelial Function and Reduces Atherosclerotic Lesion Formation in Apolipoprotein E-Deficient Mice","volume":"59","author":"Matsubara","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1161\/CIRCULATIONAHA.118.038352","article-title":"Linagliptin Effects on Heart Failure and Related Outcomes in Individuals with Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA","volume":"139","author":"McGuire","year":"2019","journal-title":"Circulation"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1111\/dom.12548","article-title":"Cardiovascular and Heart Failure Safety Profile of Vildagliptin: a Meta-Analysis of 17 000 Patients","volume":"17","author":"McInnes","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"B94","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jchf.2017.08.004","article-title":"Effects of Vildagliptin on Ventricular Function in Patients with Type 2 Diabetes Mellitus and Heart Failure","volume":"6","author":"McMurray","year":"2018","journal-title":"JACC: Heart Fail."},{"key":"B95","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1111\/dom.12116","article-title":"Cardiovascular Safety of Sulfonylureas: a Meta-Analysis of Randomized Clinical Trials","volume":"15","author":"Monami","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"B96","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.thromres.2011.12.019","article-title":"Pioglitazone Inhibits Platelet Function and Potentiates the Effects of Aspirin: a Prospective Observation Study","volume":"129","author":"Mongan","year":"2012","journal-title":"Thromb. Res."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.2337\/dc16-0542","article-title":"Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis","volume":"39","author":"Mudaliar","year":"2016","journal-title":"Dia Care"},{"key":"B98","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1210\/er.2014-1035","article-title":"Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors","volume":"35","author":"Mulvihill","year":"2014","journal-title":"Endocr. Rev."},{"key":"B99","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1001\/archinte.164.20.2273","article-title":"Impact of Diabetes on Mortality in Patients with Myocardial Infarction and Left Ventricular Dysfunction","volume":"164","author":"Murcia","year":"2004","journal-title":"Arch. Intern. Med."},{"key":"B100","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2337\/dc13-2112","article-title":"The Diabetes Control and Complications Trial\/epidemiology of Diabetes Interventions and Complications Study at 30 years: Overview","volume":"37","author":"Nathan","year":"2014","journal-title":"Dia Care"},{"key":"B101","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B102","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nm.1955","article-title":"A Shear Gradient-dependent Platelet Aggregation Mechanism Drives Thrombus Formation","volume":"15","author":"Nesbitt","year":"2009","journal-title":"Nat. Med."},{"key":"B103","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"B172","doi-asserted-by":"publisher","first-page":"e3047","DOI":"10.1002\/dmrr.3047","article-title":"Glycemic variability in the development of cardiovascular complications in diabetes","volume":"34","author":"Nusca","year":"2018","journal-title":"Diabetes Metab. Res. Rev."},{"key":"B173","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12933-019-0952-8","article-title":"Incremental role of glycaemic variability over HbA1c in identifying type 2 diabetic patients with high platelet reactivity undergoing percutaneous coronary intervention","volume":"18","author":"Nusca","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1161\/ATVBAHA.110.206425","article-title":"Glucagon-like Peptide 1 Prevents Reactive Oxygen Species-Induced Endothelial Cell Senescence through the Activation of Protein Kinase A","volume":"30","author":"Oeseburg","year":"2010","journal-title":"Atvb"},{"key":"B105","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jama.2014.16107","article-title":"Association between 7 Years of Intensive Treatment of Type 1 Diabetes and Long-Term Mortality","volume":"313","author":"Orchard","year":"2015","journal-title":"JAMA"},{"key":"B106","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1161\/CIRCULATIONAHA.119.040909","article-title":"Reconceptualization of the Molecular Mechanism by Which Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Events","volume":"140","author":"Packer","year":"2019","journal-title":"Circulation"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.jacc.2008.06.038","article-title":"Point-of-Care Measurement of Clopidogrel Responsiveness Predicts Clinical Outcome in Patients Undergoing Percutaneous Coronary Intervention","volume":"52","author":"Patti","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1016\/j.amjcard.2017.05.011","article-title":"EMPA-REG OUTCOME: The Cardiologist's Point of View","volume":"120","author":"Pham","year":"2017","journal-title":"Am. J. Cardiol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12933-019-0918-x","article-title":"Significance of Circulating microRNAs in Diabetes Mellitus Type 2 and Platelet Reactivity: Bioinformatic Analysis and Review","volume":"18","author":"Pordzik","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"E568","DOI":"10.1152\/ajpendo.00297.2009","article-title":"Vascular Actions of Insulin with Implications for Endothelial Dysfunction","volume":"297","author":"Potenza","year":"2009","journal-title":"Am. J. Physiology-Endocrinology Metab."},{"key":"B111","doi-asserted-by":"publisher","first-page":"S368","DOI":"10.2337\/diabetes.51.2007.s368","article-title":"Sulfonylurea Stimulation of Insulin Secretion","volume":"51","author":"Proks","year":"2002","journal-title":"Diabetes"},{"key":"B112","doi-asserted-by":"publisher","first-page":"e1001992","DOI":"10.1371\/journal.pmed.1001992","article-title":"The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials","volume":"13","author":"Rados","year":"2016","journal-title":"Plos Med."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.2337\/dc08-0167","article-title":"Is the Combination of Sulfonylureas and Metformin Associated with an Increased Risk of Cardiovascular Disease or All-Cause Mortality?: a Meta-Analysis of Observational Studies","volume":"31","author":"Rao","year":"2008","journal-title":"Diabetes Care"},{"key":"B174","doi-asserted-by":"publisher","first-page":"594","DOI":"10.21037\/cdt.2018.05.09","article-title":"Diabetes and antiplatelet therapy: from bench to bedside","volume":"8","author":"Rivas Rios","year":"2018","journal-title":"Cardiovasc. Diagn. Ther."},{"key":"B114","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12933-018-0682-3","article-title":"Rationale, Design, and Baseline Characteristics of the CArdiovascular Safety and Renal Microvascular outcomE Study with LINAgliptin (CARMELINA): a Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Patients with Type 2 Diabetes and High Cardio-Renal Risk","volume":"17","author":"Rosenstock","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/s0049-3848(02)00182-2","article-title":"Comparison between the Effects of the Rapid Recombinant Insulin Analog Aspart and Those of Human Regular Insulin on Platelet Cyclic Nucleotides and Aggregation","volume":"107","author":"Russo","year":"2002","journal-title":"Thromb. Res."},{"key":"B116","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1177\/174749301877871310.1016\/j.jvir.2017.11.026","article-title":"Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke: From the American Association of Neurological Surgeons (AANS), American Society of Neuroradiology (ASNR), Cardiovascular and Interventional Radiology Society of Europe (CIRSE), Canadian Interventional Radiology Association (CIRA), Congress of Neurological Surgeons (CNS), European Society of Minimally Invasive Neurological Therapy (ESMINT), European Society of Neuroradiology (ESNR), European Stroke Organization (ESO), Society for Cardiovascular Angiography and Interventions (SCAI), Society of Interventional Radiology (SIR), Society of NeuroInterventional Surgery (SNIS), and World Stroke Organization (WSO)","volume":"29","author":"Sacks","year":"2018","journal-title":"J. Vasc. Interv. Radiol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"844","DOI":"10.14740\/jocmr2760w","article-title":"Increased Hematocrit during Sodium-Glucose Cotransporter 2 Inhibitor Therapy Indicates Recovery of Tubulointerstitial Function in Diabetic Kidneys","volume":"8","author":"Sano","year":"2016","journal-title":"J. Clin. Med. Res."},{"key":"B118","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1111\/j.1538-7836.2010.03742.x","article-title":"Postprandial Hyperglycemia Is a Determinant of Platelet Activation in Early Type 2 Diabetes Mellitus","volume":"8","author":"Santilli","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"B119","doi-asserted-by":"publisher","first-page":"A1852","DOI":"10.1016\/S0735-1097(18)32393-3","article-title":"The Sglt2 Inhibitor Empagliflozin Does Not Exhibit Pro Thrombotic Effects","volume":"71","author":"Santos-Gallego","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/0006-2952(94)90379-4","article-title":"Effects of Sulfonylurea Agents on Platelet Arachidonic Acid Metabolism; Study on Platelet Homogenates","volume":"48","author":"Satoh","year":"1994","journal-title":"Biochem. Pharmacol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1160\/TH04-02-0118","article-title":"Increased Platelet Activation in Young Zucker Rats with Impaired Glucose Tolerance Is Improved by Acarbose","volume":"92","author":"Sch\u00e4fer","year":"2004","journal-title":"Thromb. Haemost."},{"key":"B122","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nrcardio.2012.183","article-title":"Cardiovascular Effects of Gliptins","volume":"10","author":"Scheen","year":"2013","journal-title":"Nat. Rev. Cardiol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1177\/193229681100500233","article-title":"The Fixed Combination of Pioglitazone and Metformin Improves Biomarkers of Platelet Function and Chronic Inflammation in Type 2 Diabetes Patients: Results from the PIOfix Study","volume":"5","author":"Sch\u00f6ndorf","year":"2011","journal-title":"J. Diabetes Sci. Technol."},{"key":"B124","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B125","doi-asserted-by":"publisher","first-page":"808","DOI":"10.2337\/diabetes.51.3.808","article-title":"Effects of Treatment with Sulfonylurea Drugs or Insulin on Ischemia-Induced Myocardial Dysfunction in Type 2 Diabetes","volume":"51","author":"Scognamiglio","year":"2002","journal-title":"Diabetes"},{"key":"B126","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1001\/archinte.168.19.2070","article-title":"Cardiovascular Outcomes in Trials of Oral Diabetes Medications","volume":"168","author":"Selvin","year":"2008","journal-title":"Arch. Intern. Med."},{"key":"B127","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.2337\/dc17-1091","article-title":"Causes of Death in a Contemporary Cohort of Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights from the TECOS Trial","volume":"40","author":"Sharma","year":"2017","journal-title":"Dia Care"},{"key":"B128","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s11239-008-0301-3","article-title":"Effect of Acarbose on Platelet-Derived Microparticles, Soluble Selectins, and Adiponectin in Diabetic Patients","volume":"28","author":"Shimazu","year":"2009","journal-title":"J. Thromb. Thrombolysis"},{"key":"B129","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/j.jacc.2003.04.001","article-title":"The Effects of Rosiglitazone, a Peroxisome Proliferator-Activated Receptor-Gamma Agonist, on Markers of Endothelial Cell Activation, C-Reactive Protein, and Fibrinogen Levels in Non-diabetic Coronary Artery Disease Patients","volume":"42","author":"Sidhu","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"B130","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1111\/bph.13831","article-title":"Influence of Inflammation and Nitric Oxide upon Platelet Aggregation Following Deposition of Diesel Exhaust Particles in the Airways","volume":"174","author":"Smyth","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.2337\/db11-1806","article-title":"Postprandial Platelet Activation Is Related to Postprandial Plasma Insulin rather Than Glucose in Patients with Type 2 Diabetes","volume":"61","author":"Spectre","year":"2012","journal-title":"Diabetes"},{"key":"B132","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.thromres.2016.03.009","article-title":"Meal-induced Platelet Activation in Diabetes Mellitus Type 1 or Type 2 Is Related to Postprandial Insulin rather Than Glucose Levels","volume":"141","author":"Spectre","year":"2016","journal-title":"Thromb. Res."},{"key":"B133","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12933-020-01016-5","article-title":"Sodium-glucose Cotransporter 2 Inhibitors Antagonize Lipotoxicity in Human Myeloid Angiogenic Cells and ADP-dependent Activation in Human Platelets: Potential Relevance to Prevention of Cardiovascular Events","volume":"19","author":"Spigoni","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.2337\/db05-1543","article-title":"Hyperglycemia Stimulates Coagulation, whereas Hyperinsulinemia Impairs Fibrinolysis in Healthy Humans","volume":"55","author":"Stegenga","year":"2006","journal-title":"Diabetes"},{"key":"B135","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1111\/bph.13549","article-title":"Glucagon-like Peptide-1 Receptor Signalling Reduces Microvascular Thrombosis, Nitro-Oxidative Stress and Platelet Activation in Endotoxaemic Mice","volume":"174","author":"Steven","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"B136","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.redox.2017.06.009","article-title":"The SGLT2 Inhibitor Empagliflozin Improves the Primary Diabetic Complications in ZDF Rats","volume":"13","author":"Steven","year":"","journal-title":"Redox Biol."},{"key":"B137","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1160\/TH12-06-0397","article-title":"Effects of Pioglitazone on Platelet P2Y12-Mediated Signalling in Clopidogrel-Treated Patients with Type 2 Diabetes Mellitus","volume":"108","author":"Suryadevara","year":"2012","journal-title":"Thromb. Haemost."},{"key":"B139","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1056\/NEJMoa1504347","article-title":"Excess Mortality Among Persons with Type 2 Diabetes","volume":"373","author":"Tancredi","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B140","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ejphar.2010.09.009","article-title":"Glybenclamide: an Antidiabetic with In Vivo Antithrombotic Activity","volume":"649","author":"Ting","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"B141","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0021-9150(82)90069-7","article-title":"Metformin Reduces Platelet Hypersensitivity in Hypercholesterolemic Rabbits","volume":"41","author":"Tremoli","year":"1982","journal-title":"Atherosclerosis"},{"key":"B142","doi-asserted-by":"publisher","first-page":"dc141850","DOI":"10.2337\/dc14-1850","article-title":"Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial","volume":"38","author":"Udell","year":"2015","journal-title":"Dia Care"},{"key":"B143","doi-asserted-by":"publisher","first-page":"k4365","DOI":"10.1136\/bmj.k4365","article-title":"Sodium Glucose Cotransporter 2 Inhibitors and Risk of Serious Adverse Events: Nationwide Register Based Cohort Study","volume":"363","author":"Ueda","year":"2018","journal-title":"BMJ"},{"key":"B144","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1210\/er.2011-1052","article-title":"Cardiovascular Biology of the Incretin System","volume":"33","author":"Ussher","year":"2012","journal-title":"Endocr. Rev. Endocr Rev"},{"key":"B145","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1055\/a-0787-1382","article-title":"Use of Metformin and Platelet Reactivity in Diabetic Patients Treated with Dual Antiplatelet Therapy","volume":"129","author":"Verdoia","year":"2021","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"B146","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.2337\/diacare.24.8.1476","article-title":"Platelet Dysfunction in Type 2 Diabetes","volume":"24","author":"Vinik","year":"2001","journal-title":"Diabetes Care"},{"key":"B147","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1185\/03007998209112384","article-title":"The Effects of Gliclazide on Platelet Function in Patients with Diabetes Mellitus","volume":"8","author":"Violi","year":"1982","journal-title":"Curr. Med. Res. Opin."},{"key":"B148","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.ahj.2014.07.016","article-title":"Pioglitazone for Secondary Prevention after Ischemic Stroke and Transient Ischemic Attack: Rationale and Design of the Insulin Resistance Intervention after Stroke Trial","volume":"168","author":"Viscoli","year":"2014","journal-title":"Am. Heart J."},{"key":"B149","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/09537109976347","article-title":"Inhibitory Effect of Glyburide on Thrombin-Induced Platelet Aggregation and Phosphoinositide Metabolism in Normal Human Platelets","volume":"10","author":"Wada","year":"1999","journal-title":"Platelets"},{"key":"B150","doi-asserted-by":"publisher","first-page":"4888","DOI":"10.1073\/pnas.95.9.4888","article-title":"Mechanism of Platelet Inhibition by Nitric Oxide: In Vivo Phosphorylation of Thromboxane Receptor by Cyclic GMP-dependent Protein Kinase","volume":"95","author":"Wang","year":"1998","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B151","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes","volume":"369","author":"White","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B152","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1111\/dom.12951","article-title":"Cardiovascular Safety of Vildagliptin in Patients with Type 2 Diabetes: A European Multi-Database, Non-interventional Post-authorization Safety Study","volume":"19","author":"Williams","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"B153","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1161\/CIRCULATIONAHA.108.791061","article-title":"Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy with Prasugrel in Patients with Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38","volume":"118","author":"Wiviott","year":"2008","journal-title":"Circulation"},{"key":"B154","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ahj.2018.01.012","article-title":"The Design and Rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial","volume":"200","author":"Wiviott","year":"2018","journal-title":"Am. Heart J."},{"key":"B155","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B156","doi-asserted-by":"publisher","first-page":"36222","DOI":"10.1038\/srep36222","article-title":"Metformin Uniquely Prevents Thrombosis by Inhibiting Platelet Activation and mtDNA Release","volume":"6","author":"Xin","year":"2016","journal-title":"Sci. Rep."},{"key":"B157","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.1002\/jcp.26760","article-title":"Sodium-glucose Cotransporter Inhibitors and Oxidative Stress: An Update","volume":"234","author":"Yaribeygi","year":"2019","journal-title":"J. Cel Physiol."},{"key":"B158","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s11892-013-0378-8","article-title":"The Future of Thiazolidinedione Therapy in the Management of Type 2 Diabetes Mellitus","volume":"13","author":"Yau","year":"2013","journal-title":"Curr. Diab Rep."},{"key":"B159","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 Inhibitors for Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Type 2 Diabetes: a Systematic Review and Meta-Analysis of Cardiovascular Outcome Trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"The Lancet"},{"key":"B160","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/1475-2840-12-73","article-title":"Effects of 24-week Treatment with Acarbose on Glucagon-like Peptide 1 in Newly Diagnosed Type 2 Diabetic Patients: a Preliminary Report","volume":"12","author":"Zheng","year":"2013","journal-title":"Cardiovasc. Diabetol."},{"key":"B161","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1001\/jama.2018.3024","article-title":"Association between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors with All-Cause Mortality in Patients with Type 2 Diabetes","volume":"319","author":"Zheng","year":"2018","journal-title":"JAMA"},{"key":"B162","doi-asserted-by":"publisher","first-page":"e3173","DOI":"10.1002\/dmrr.3173","article-title":"Mechanisms of Action of Metformin with Special Reference to Cardiovascular Protection","volume":"35","author":"Zilov","year":"2019","journal-title":"Diabetes Metab. Res. Rev."},{"key":"B163","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.670155\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T03:00:29Z","timestamp":1620788429000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.670155\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,12]]},"references-count":166,"alternative-id":["10.3389\/fphar.2021.670155"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.670155","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,12]]},"article-number":"670155"}}